Hepatomegaly
11
2
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.1%
1 terminated out of 11 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (11)
Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
Biomarker for Farber Disease (BioFarber)
Biomarker for Gaucher Disease: BioGaucher (BioGaucher)
Biomarker for Sly Disease (MPS VII) (BioSly)
Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis
Prevalence of Hepatomegaly in Children and Adolescents With Type 1 Diabetes Mellitus
Octreotide in Severe Polycystic Liver Disease
Lanreotide as Treatment of Polycystic Livers
Open-Label Extension of LOCKCYST Trial